More recently, an international survey demonstrated that a majority of lung cancer oncologists understand that improved survival is associated with therapies selected after epidermal growth factor receptor (EGFR) mutation testing, but a quarter of lung cancer oncologists do not consider the specific EGFR mutation detected in making therapeutic decisions [4]. Here, EGFR is linked to lung cancer.